ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

ADAM9

ADAM metallopeptidase domain 9 · also MDC9, KIAA0021, MCMP, Mltng · ADAM metallopeptidase domain containing

3 programs in company-led studies act on ADAM9, from 3 companies: 0 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
Anti-ADAM9/Exatecan Antibody-drug Conjugate MGC028ruleMacroGenics–phase 111 running–NCIt
Anti-ADAM9/Pamirtecan Antibody-drug Conjugate DB-1317ruleDualityBio–phase 111 running–NCIt
Anti-ADAM9/Topoisomerase-1 Inhibitor Antibody-drug Conjugate BG-C0979ruleBeOne Medicines–phase 111 running–NCIt

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.